NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday that its first quarter 2014 revenues grew 6 percent, driven by an 18 percent spike in assay sales, as well as an increase in consumables sales.

Austin, Texas-based Luminex reported total revenues of $56.6 million for the three months ended March 31, compared to revenues of $53.2 million for the first quarter of 2013. It beat the consensus Wall Street estimate for revenues of $55.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.